Clinical trial · Observational
COMPARATIVE EFFECTS OF PERIOPERATIVE AND ADJUVANT CHEMOTHERAPY ON OUTCOMES OF OPERABLE GASTRIC CANCER: EXPERIENCE FROM A CANCER CARE CENTER
NCT04989764CI-TRIAL-00053077completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* Patients with gastric adenocarcinoma * Comparison: perioperative chemotherapy vs. adjuvant therapy. * Sample size differences between the two groups. * Kaplan meier survival analysis, overall survival and disease free survival
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer, Outcomes, Pakistan, Adjuvant Chemotherapy, Perioperative Chemotherapy | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- perioperative chemotherapy vs. adjuvant therapy in gastric ca patients
- label
- perioperative chemotherapy group vs. adjuvant chemotherapy group
Primary outcomes (2)
- measure
- The overall survival
- timeFrame
- from January 2015 till December 2019
- description
- The overall survival (OS) was defined as the length of the time from date of diagnosis till last follow-up or death
- measure
- The disease-free survival
- timeFrame
- from January 2015 till December 2019
- description
- The disease free survival (DFS) as the length of the time from date of last treatment which is either perioperative or adjuvant chemotherapy to tumor relapse or death.
Eligibility
Eligibility (as posted)
Show eligibility criteria text
Inclusion Criteria: * We included histologically proven gastric adenocarcinoma patient with operable disease and the patients who completed their prescribed perioperative or adjuvant chemotherapy cycles Exclusion Criteria: * Patients were excluded if they had Tis or T1, N0 disease, inoperable disease, metastatic. In addition, all those who did not undergo adequate lymphadenectomy (\< D2) or had R1 margins following surgery were excluded
References
Publications (0)
Data not yet available
No reference posted for this study.